Drug intelligence / Profile preview

REC-01

Development stage: Unknown
Lead developer: PuREC
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

REC-01 is a high-purity mesenchymal stem cell (MSC) product derived from donor bone marrow, developed by PuREC Co., Ltd. using its proprietary cell selection technology. It is specifically designed for the treatment of severe pediatric hypophosphatasia (HPP), a rare genetic disorder characterized by defective bone mineralization due to a deficiency in tissue-nonspecific alkaline phosphatase (TNSALP). REC-01 is intended to be administered alongside umbilical cord blood transplantation (UCBT) to provide a sustainable source of alkaline phosphatase-producing cells. The product is currently being evaluated in a Phase I/IIa clinical trial in Japan for patients who are already receiving asfotase alfa but require additional therapeutic support.

Other names: high-purity mesenchymal stem cells

Beyond the preview

Go deeper on REC-01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on REC-01.

Explore the full profile